Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

	Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
	Li, Ning 7; Zhang, Youzhong 8; Wang, Jing 9; Zhu, Jianqing 10; Wang, Li 11; Wu, Xiaohua 12; Yao, Desheng 13; Wu, Qiang 14; Liu, Jihong 15; Tang, Junying 16
刊名	GYNECOLOGIC ONCOLOGY
	2021-08-01
卷号	162
ISSN号	0090-8258
WOS研究方向	Oncology ; Obstetrics & Gynecology
语种	英语
出版者	ACADEMIC PRESS INC ELSEVIER SCIENCE
WOS记录号	WOS:000687070800098
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125046]
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Univ, Sch Med, Womans Hosp, Hangzhou, Peoples R China 2.Beijing Canc Hosp, Beijing, Peoples R China 3.Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China 4.Tianjin Cent Hosp Gynecol Obstet, Tianjin, Peoples R China 5.Liaoning Canc Hosp & Insititute, Shenyang, Liaoning, Peoples R China 6.Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China 7.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China 8.Shandong Univ, Qilu Hosp, Jinan, Shandong, Peoples R China 9.Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China 10.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Li, Ning,Zhang, Youzhong,Wang, Jing,et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial[J]. GYNECOLOGIC ONCOLOGY,2021,162.
APA	Li, Ning.,Zhang, Youzhong.,Wang, Jing.,Zhu, Jianqing.,Wang, Li.,...&Wu, Lingying.(2021).Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial.GYNECOLOGIC ONCOLOGY,162.
MLA	Li, Ning,et al."Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial".GYNECOLOGIC ONCOLOGY 162(2021).